- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xenon Pharmaceuticals Inc (XENE)
Xenon Pharmaceuticals Inc stock price live, this page displays NASDAQ XENE stock exchange data. View the XENE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Xenon Pharmaceuticals Inc real time stock price chart below.
What Is the Xenon Pharmaceuticals Inc Stock Price Today?
The Xenon Pharmaceuticals Inc stock price today is 32.68.
What Is the Stock Symbol for Xenon Pharmaceuticals Inc?
The stock symbol for Xenon Pharmaceuticals Inc is ""XENE.""
What Stock Exchange Does Xenon Pharmaceuticals Inc Trade On?
Xenon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xenon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xenon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XENE quote. (ISIN: CA98420N1050)
What Is the Xenon Pharmaceuticals Inc Stock Price Today?
The Xenon Pharmaceuticals Inc stock price today is 32.68.
What Is the Stock Symbol for Xenon Pharmaceuticals Inc?
The stock symbol for Xenon Pharmaceuticals Inc is ""XENE.""
What Stock Exchange Does Xenon Pharmaceuticals Inc Trade On?
Xenon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xenon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xenon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XENE quote. (ISIN: CA98420N1050)
32.68
+1.26(+4.01%)
Closed·
After Hours
32.680.00(0.00%)
·
Fair Value
An estimate of a Xenon Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.65
33.51
52 wk Range
26.74
46.00
XENE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
XENE is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Xenon Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.6533.51
52 wk Range
26.7446.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XENE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Xenon Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
55.23
Upside
+69.01%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
7 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Xenon Pharmaceuticals Inc Company Profile
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc SWOT Analysis
Azetukalner's Promise | Xenon's lead drug candidate shows potential in epilepsy and major depressive disorder, with blockbuster sales projections and upcoming clinical milestones |
Pipeline Progress | Explore Xenon's robust clinical development program, including Phase 3 trials for focal onset seizures and plans for MDD studies |
Market Opportunity | Delve into the substantial market potential for azetukalner, with analysts projecting over $1 billion in sales within 3-5 years post-launch |
Financial Health | Learn about Xenon's strong liquidity position and analyst optimism, with price targets ranging from $55 to $65, despite current unprofitability |
Xenon Pharmaceuticals Inc Earnings Call Summary for Q4/2024
- Xenon Pharmaceuticals reported Q4 2024 EPS of -0.84, slightly beating -0.85 forecast; stock fell 2.02% in regular trading, 0.81% after hours
- Company plans significant R&D spending increase in 2025-2026 for multiple Phase 3 programs, including epilepsy and bipolar depression studies
- Strong cash position of $754.4M extends runway into 2027; CFO Sherry Allen announced intention to step down by June 2025
- CEO expressed optimism about AZETU Calnar as potential "best-in-class anti-seizure medication"; NDA submission expected H2 2025
- Analysts maintain strong buy consensus; price targets range $43-$67 despite -22.81% one-year total return
Last Updated: 28/02/2025, 00:00
Read Full TranscriptCompare XENE to Peers and Sector
Metrics to compare | XENE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXENEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.6x | −5.2x | −0.5x | |
PEG Ratio | 0.50 | 0.00 | 0.00 | |
Price/Book | 3.4x | 2.3x | 2.6x | |
Price / LTM Sales | 321.5x | 8.8x | 3.1x | |
Upside (Analyst Target) | 75.0% | 145.1% | 47.8% | |
Fair Value Upside | Unlock | 5.1% | 6.9% | Unlock |
Analyst Ratings
19 Buy
0 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 55.23
(+69.01% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.83 / -0.91
Revenue / Forecast
7.50M / 1.25M
People Also Watch
FAQ
What Stock Exchange Does Xenon Pharmaceuticals Trade On?
Xenon Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Xenon Pharmaceuticals?
The stock symbol for Xenon Pharmaceuticals is "XENE."
What Is the Xenon Pharmaceuticals Market Cap?
As of today, Xenon Pharmaceuticals market cap is 2.50B.
What Is Xenon Pharmaceuticals's Earnings Per Share (TTM)?
The Xenon Pharmaceuticals EPS (TTM) is -3.22.
When Is the Next Xenon Pharmaceuticals Earnings Date?
Xenon Pharmaceuticals will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is XENE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Xenon Pharmaceuticals Stock Split?
Xenon Pharmaceuticals has split 0 times.
How Many Employees Does Xenon Pharmaceuticals Have?
Xenon Pharmaceuticals has 322 employees.
What is the current trading status of Xenon Pharmaceuticals (XENE)?
As of 09 Jul 2025, Xenon Pharmaceuticals (XENE) is trading at a price of 32.68, with a previous close of 31.42. The stock has fluctuated within a day range of 31.65 to 33.51, while its 52-week range spans from 26.74 to 46.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.